Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency
Authors
Keywords
-
Journal
ONCOGENE
Volume 35, Issue 29, Pages 3854-3865
Publisher
Springer Nature
Online
2015-12-14
DOI
10.1038/onc.2015.456
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The biology and management of systemic anaplastic large cell lymphoma
- (2015) G. Hapgood et al. BLOOD
- Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK+ Tumors
- (2015) A. D. Amin et al. CANCER RESEARCH
- Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine
- (2015) R. Katayama et al. CLINICAL CANCER RESEARCH
- The next-generation ALK inhibitors
- (2015) Georg Pall CURRENT OPINION IN ONCOLOGY
- NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922
- (2015) Luca Mologni et al. Oncotarget
- ALK-Dependent Control of Hypoxia-Inducible Factors Mediates Tumor Growth and Metastasis
- (2014) C. Martinengo et al. CANCER RESEARCH
- Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib
- (2014) R. Katayama et al. CLINICAL CANCER RESEARCH
- DNA Replication and Oncogene-Induced Replicative Stress
- (2014) Stephanie A. Hills et al. CURRENT BIOLOGY
- Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma
- (2014) Daria Zdzalik et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Crizotinib in Advanced, Chemoresistant Anaplastic Lymphoma Kinase–Positive Lymphoma Patients
- (2014) Carlo Gambacorti Passerini et al. JNCI-Journal of the National Cancer Institute
- Next-Generation Sequencing Reveals a Novel NSCLC ALK F1174V Mutation and Confirms ALK G1202R Mutation Confers High-Level Resistance to Alectinib (CH5424802/RO5424802) in ALK-Rearranged NSCLC Patients Who Progressed on Crizotinib
- (2014) Sai-Hong Ignatius Ou et al. Journal of Thoracic Oncology
- Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK–Positive Anaplastic Large Cell Lymphoma
- (2014) M. Ceccon et al. MOLECULAR CANCER RESEARCH
- Myc and Ras oncogenes engage different energy metabolism programs and evoke distinct patterns of oxidative and DNA replication stress
- (2014) Apolinar Maya-Mendoza et al. Molecular Oncology
- Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
- (2014) Chong Sun et al. NATURE
- Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer
- (2014) L. Friboulet et al. Cancer Discovery
- Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias
- (2013) C. J. Walker et al. BLOOD
- Intermittent BRAF-inhibitor therapy is a feasible option: report of a patient with metastatic melanoma
- (2013) A. Koop et al. BRITISH JOURNAL OF DERMATOLOGY
- KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia
- (2013) Julia Etchin et al. BRITISH JOURNAL OF HAEMATOLOGY
- Excessive MET signaling causes acquired resistance and addiction to MET inhibitors in the MKN45 gastric cancer cell line
- (2013) Yohei Funakoshi et al. INVESTIGATIONAL NEW DRUGS
- Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
- (2013) Meghna Das Thakur et al. NATURE
- Mechanisms of Resistance to Crizotinib in Patients withALKGene Rearranged Non–Small Cell Lung Cancer
- (2012) Robert C. Doebele et al. CLINICAL CANCER RESEARCH
- The battle against ALK resistance: successes and setbacks
- (2012) Claudia Voena et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Inhibitors of the anaplastic lymphoma kinase
- (2012) Luca Mologni EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors
- (2012) M. Ceccon et al. MOLECULAR CANCER RESEARCH
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
- (2012) R. Katayama et al. Science Translational Medicine
- Extracellular Signal-Regulated Kinases Modulate DNA Damage Response - A Contributing Factor to Using MEK Inhibitors in Cancer Therapy
- (2011) F. Wei et al. CURRENT MEDICINAL CHEMISTRY
- Conversion from the “oncogene addiction” to “drug addiction” by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation
- (2011) Kenichi Suda et al. LUNG CANCER
- Crizotinib in Anaplastic Large-Cell Lymphoma
- (2011) Carlo Gambacorti-Passerini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Checkpoint control and cancer
- (2011) R H Medema et al. ONCOGENE
- Oncogenic Stress Induced by Acute Hyper-Activation of Bcr-Abl Leads to Cell Death upon Induction of Excessive Aerobic Glycolysis
- (2011) Michael A. Dengler et al. PLoS One
- EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
- (2010) Young Lim Choi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- NPM-ALK inhibits the p53 tumor suppressor pathway in an MDM2 and JNK-dependent manner
- (2009) Y.-X. Cui et al. BLOOD
- An Oncogene-Induced DNA Damage Model for Cancer Development
- (2008) T. D. Halazonetis et al. SCIENCE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now